

Synthesis of Hemilabile P,N Ligands: ω -2-Pyridyl-*n*-alkylphosphines

Achim Jansen and Stephan Pitter*

Projektgruppe CO₂-Chemie, Friedrich-Schiller-Universität Jena, D-07743 Jena, Germany

Summary. A series of P,N ligands of the general formula (2-*py*)-(CH₂)_{*n*}-PR₂ (2-*py*: 2-pyridyl; *R*: *i*-Pr (*n* = 1, 4–7), Ph (*n* = 5–7)) **4a–g** and **6a** has been synthesized. Starting from 2-picoline (**1**), 2-(ω -chloroalkyl)pyridines **3a–d** are prepared. The reactions of **3a–d** with (*i*-Pr)₂PLi and Ph₂PLi, respectively, result in the title compounds **4a–g** in up to 89% yield. Reaction of Cl-(CH₂)₃-P(*i*-Pr)₂ with 2-picolylithium (**2**) is an alternative route to **4a**. Additionally, P,P,N ligands **7a** and **9** are synthesized by similar methods. All new compounds were fully characterized. The formation of cyclic pyridinium derivatives **5a** and **5b** from intramolecular S_N reactions of **3a** and **3b** is discussed in detail.

Keywords. Hemilabile ligand; P,N Ligand.

Synthese hemilabiler P,N-Liganden: ω -2-Pyridyl-*n*-alkylphosphine

Zusammenfassung. Ausgehend von 2-Picolin (**1**) werden die homologen P,N-Liganden (2-*py*)-(CH₂)_{*n*}-PR₂ (2-*py*: 2-Pyridyl; *R*: *i*-Pr (*n* = 1, 4–7), Ph (*n* = 5–7)) **4a–g** und **6a** dargestellt. Über die entsprechenden 2-(ω -Chloralkyl)pyridine **3a–d** erhält man durch nachfolgende Umsetzung mit (*i*-Pr)₂PLi bzw. Ph₂PLi die Titelverbindungen **4a–g** in bis zu 89% Ausbeute. Alternativ erhält man Verbindung **4a** durch Umsetzung von Cl-(CH₂)₃-P(*i*-Pr)₂ mit 2-Picolylithium (**2**). Ähnliche Synthesemethoden eröffnen einen einfachen Zugang zu den P,P,N-Liganden **7a** und **9**. Alle neuen Verbindungen wurden vollständig charakterisiert. Die Bildung der zyklischen Pyridiniumderivate **5a** und **5b** durch intramolekulare S_N-Reaktionen von **3a** bzw. **3b** wird im Detail diskutiert.

Introduction

Bidentate ligands which offer two different coordination sites are termed to be hemilabile [1]. They provide interesting properties in catalytic reactions: Fixed at the metal centre by one strong donor group, the number of coordination sites may be varied by addition or removal of the weaker donor group. This hemilability may play an important role during a catalytic cycle because key intermediates are often stabilized by weaker donor ligands, *e.g.* solvent molecules. Most recently, we were able to show that ω -cyano-*n*-alkylphosphines exhibit an extraordinary effect on the cooligomerization of 1,3-butadiene and carbon dioxide due to labile bonding of the nitrile backbone to the active centre [2, 3]. Consequently, catalysts with hemilabile

* Corresponding author

ligands may decrease the enthalpy of activation for fundamental reactions of the catalytic cycle.

Similar P,N ligands with one phosphino and one pyridyl moiety have attracted considerable interest in the remaining decade [4]. They offer unique properties in some catalytic reactions like the alkoxycarbonylation of alkynes [5]. Other recent fields of interest are the synthesis of heterobimetallic complexes [6] or studies on novel organic reactions [7]. Phosphinopyridines are often fixed in sterically rigid systems: As ligands, they tend to form stable *cis* chelate complexes [4]. Phosphinopyridines with $(\text{CH}_2)_n$ chains ($n > 3$) as spacers are rare [8]. Increasing the number of spacer atoms should decrease the tendency to form chelate complexes and therefore might have a significant influence on catalytic processes.


In order to study the behaviour of phosphinopyridines with variable spacer lengths in catalytic systems as well as in the formation of mononuclear complexes, our aim was to establish their synthetic approach. In this report, we describe the preparation and properties of a variety of ω -2-pyridyl-*n*-alkylphosphines and of some related P,P,N ligands.

Results and Discussion


α -Metalation of 2-picoline (**1**) provides an easy access to further substitution with alkyl halides [9]. Two routes for the syntheses of ω -2-pyridyl-*n*-alkylphosphines were examined (Scheme 1).

After metalation of **1**, the reaction with α -bromo- ω -chloro-*n*-alkanes affords **3a–d** in up to 94% yield. Interestingly, **3a** and **3b** undergo intramolecular S_N reactions to chlorides **5a** and **5b** (Scheme 2). Similar cyclic pyridinium salts have been synthesized by other methods [10–12]. The C,N stretching frequencies of the pyridine moiety shift from 1561 and 1591 cm^{-1} to 1635 and 1583 cm^{-1} , indicating a positive charge at the nitrogen. In particular, all attempts to purify **3a** result in low yield.

3c and **3d** do not yield cyclic pyridinium salts as consecutive products. Obviously, the reaction is controlled by the formation of thermodynamically favoured ring sizes in the case of **3a** and **3b**. Molecular mass determination of **5a**



Scheme 1. Synthesis of **4a–d** (R : *i*-Pr, $n = 4\text{--}7$) and **4e–g** (R : Ph, $n = 5\text{--}7$)

**Scheme 2.** Intramolecular reactions of **3a** and **3b**

via measuring the osmotic pressure in chloroform solution indicates the existence of a dimer species. Dimers are also indicated by the FAB mass spectrum of **5a** and the EI mass spectrum of **5b**, whereas the EI mass spectrum of **5a** and the FAB mass spectrum of **5b** indicate monomeric structures. The NMR spectra of **5a** and **5b** are in good agreement with the analogous iodide derivatives reported by *Murphy et al.* [12, 13].

Attempts to quantify the reaction enthalpy of the ring closure reaction by differential scanning calorimetry were not successful because of interference of the exothermic reaction with rapid crystallization of nascent **5a** and **5b**, respectively. The reaction of **3a** in CDCl₃ solution is slow enough to be followed by NMR spectroscopy (Fig. 1). The rate constant of this first order reaction is calculated to be $1.38 \cdot 10^{-5} \text{ s}^{-1}$ with a half time of 14 h at 298 K, corresponding to an


**Fig. 1.** Relative integral values of selected ¹H NMR resonances for the reaction of **3a** to **5a** at 298 K (Scheme 2, Experimental); $\sum Int_{(H)} \{(\text{Et}_3\text{Si})_2\text{O}\} = 100$

Table 1. Selected spectroscopic data of P,N and P,P,N ligands

	$\delta(^{31}\text{P})/\text{ppm}$	$\nu_{\text{C}=\text{N}}/\text{cm}^{-1}$	Ref.
4a	4.4	1590, 1569	^a
4b	3.2	1590, 1569	^a
4c	4.5	1590, 1569	^a
4d	4.4	1590, 1569	^a
4e	-15.6	1589, 1566	^a
4f	-15.5	1598, 1586, 1567	^a
4g	-15.5	1587, 1568	^a
6a	13.3	1591, 1567	^a
6b	-10.1 ^b	1589, 1580, 1567 ^b	[14]
7a	12.6	1584, 1565	^a
7b	-4.5	1580	[15]
9	12.7	1587, 1573	^a
10	-9.1	1589, 1579, 1568 ^b	[17]

^a This work; ^b previously not reported, ³¹P NMR spectra in CDCl₃

intramolecular pathway (Scheme 2). In *THF* solution, the ring closure of **3a** is very slow, and **3b** is fairly stable in most common solvents.


3a is less suitable than **3b–d** for further reaction with lithium phosphides (cf. Scheme 1). The desired products **4b–g** are obtained in 67–89% yield after purification. The yield of **4a** (9%) is low over both steps due to the low yield of **3a**. The analogous reaction of **3a** with Ph₂PLi yields a product mixture: Attempts to purify the desired product by distillation or column chromatography have not been successful. **4a** may be alternatively synthesized (Scheme 1, lower part). As a side product, (*i*-Pr)₂P-(CH₂)₆-P(*i*-Pr)₂ is formed resulting from a metal halogen exchange in Cl-(CH₂)₃-P(*i*-Pr)₂ followed by reaction with a second molecule Cl(CH₂)₃-P(*i*-Pr)₂.

Spectroscopic data of **4a–g** (Table 1; Experimental) are in agreement with their constitution. The AX₃ spin systems of the diastereotopic methyl groups in **4a–d** (also in **6a**, **7a**, and **9**) are not resolved in CDCl₃ solution. To verify the *J*_{H,H} and the *J*_{H,P} coupling constants, ¹H NMR spectra were also acquired in C₆D₆ solution.

As expected, the phenyl substituted phosphines **4e–g** are moderately stable after purification. The diisopropylphosphino derivatives **4a–d** undergo fast decomposition when exposed to air.

1 is also suitable to allow elegant access to potential terdentate ligands. In analogy to *Pignolet* and coworkers [15], stepwise metalation of **1** and reaction with (*i*-Pr)₂P-Cl or Ph₂P-Cl yield P,N ligands **6a** and **6b** [14] and then the symmetrical P,P,N ligands **7a** and **7b** (Scheme 3) [15]. When metalation of **1** is performed with LDA instead of *n*-BuLi, secondary reaction with Ph₂P-Cl affords Ph₂P-N(*i*-Pr)₂ [16]. In **7a**, there are two diastereotopic P(*i*-Pr)₂ groups, resulting in a magnetic inequivalence of the CH groups bound to each phosphorus and a duplication of the CH₃ signals in the ¹H and ¹³C NMR spectra.

Analogous to the synthesis of 2,6-*bis*-(diphenylphosphino-methyl)-pyridine **10**, [17, 18], the diisopropylphosphino derivative **9** is accessible *via* reaction of 2,6-



Scheme 3. Synthesis of P,P,N ligands (*R*: *i*-Pr for **6a**, **7a**; Ph for **6b**, **7b**)

bis(chloromethyl)-pyridine **8** with (*i*-Pr)₂PLi. **9** is expected to form highly stable chelate complexes.

Investigations on the coordination behaviour of these new hemilabile ligands and, in particular, details on their application to catalysis will be reported separately.

Experimental

All manipulations were carried out under an atmosphere of dry argon by standard *Schlenk* techniques. Solvents were distilled prior to use after purification with standard methods. Commercially available reagents were used as received or freshly degassed. **6b** [14], **7b** [15], **10** [17], and Cl-(CH₂)₃-(*i*-Pr)₂ [2] were prepared according to literature methods.

Physical measurements

NMR spectra were acquired on a Bruker AC 200 spectrometer (¹H: 200.13 MHz, ¹³C: 50.32 MHz, ³¹P: 81.02 MHz) at 298 K. Chemical shifts are referenced to internal or external *TMS* (¹H, ¹³C) or to external 85% H₃PO₄ (³¹P). In experiments using non-deuterated solvents, a coaxial tube with D₂O serving as lock substance was inserted. Assignments were confirmed by ¹H,¹H-COSY, ¹H,¹³C-HETCOR, ¹³C-DEPT, and selective ³¹P decoupling of ¹H and ¹³C{¹H} NMR spectra. Coupling constants are given in Hz.

The kinetic measurement for the reaction of **3a** to **5a** was performed with a 0.1745 mol · dm⁻³ CDCl₃ solution of **3a** and hexaethyldisiloxane (0.1712 mol · dm⁻³) as an internal standard; ¹H NMR spectra were acquired at 298 K every 15 min until nearly complete conversion of **2a**.

Mass spectra (EI: 70 eV, CI: H₂O, FAB: glycerine) were recorded on a Finigan SSQ 710 instrument. For GC-MS analysis, a Hewlett Packard 5890/5972 (He, 30 m HP5-MS capillary column) system was used. IR measurements were performed on a Perkin Elmer PC-16 spectrometer. The results of the elemental analyses agreed satisfactorily with the theoretical values.

General procedure for the synthesis of 2-(ω -chloroalkyl)pyridines

2-Picoline is added dropwise to a freshly prepared solution of one equivalent *LDA* in *THF* at -50°C. After stirring for 3 h at room temperature, the dark red solution of lithiated picoline is transferred *via* a canula to a well-stirred solution of α -bromo- ω -chloro-*n*-alkane in thf (2 cm³ per 1 mmol) at

$-50^{\circ}\text{C}^{\text{a}}$. The mixture is stirred for 36 h at room temperature to complete reaction. After distillation of the solvent the residue is hydrolyzed with water (1 cm^3 per 1 mmol). The organic layer is separated, and the aqueous phase is extracted four times with diethyl ether. The combined organic phases are dried over Na_2SO_4 , and the solvent is removed under vacuum. Fractionation on a 20 cm *Vigreux* column affords the products as light yellow viscous liquids.

2-(4-Chlorobutyl)-pyridine, (**3a**; $\text{C}_9\text{H}_{12}\text{ClN}$)

Following the procedure described above, reaction of 4.66 g (50 mmol) **1** and 7.87 g (50 mmol) 1-bromo-3-chloro-propane affords the crude product which is dissolved in 10 cm^3 pentane, filtered over silica, and dried under vacuum to give 1.27 g (7.5 mmol, 15%) of **2a** (b.p.: 58°C at $4 \cdot 10^{-6}$ mbar). Pure **3a** slowly decomposes at -78°C .

^1H NMR (CDCl_3): $\delta = 8.51$ (d, $^3J = 4.6$, 1H, H-6), 7.58 (dt, $^3J = 7.6$, $^4J = 1.9$, 1H, H-4), 7.10 (m, 2H, H-3/5), 3.54 (t, $^3J = 6.2$, 2H, H-10), 2.80 (t, $^3J = 7.3$, 2H, H-7), 1.85 (m, 4H, H-8/9) ppm; ^{13}C NMR (CDCl_3): $\delta = 161.4$ (C-2), 149.2 (C-6), 136.2 (C-4), 122.6 (C-3), 121.0 (C-5), 44.7 (C-10), 37.3 (C-7), 32.0 (C-9), 26.8 (C-8) ppm.

2-(5-Chloropentyl)-pyridine (**3b**; $\text{C}_{10}\text{H}_{14}\text{ClN}$)

Reaction of 5.59 g (60 mmol) **1** and 10.29 g (60 mmol) 1-bromo-4-chloro-butane affords 7.97 g (43 mmol, 72%) of **2b** (b.p.: 72°C at 0.01 mbar), which is stable at -30°C .

^1H NMR (CDCl_3): $\delta = 8.50$ (ddd, $^3J = 4.9$, $^4J = 1.9$, $^5J = 1.0$, 1H, H-6), 7.55 (dt, $^3J = 7.7$, $^4J = 1.9$, 1H, H-4), 7.08 (m, 2H, H-3/5), 3.50 (t, $^3J = 6.6$, 2H, H-11), 2.77 (t, $^3J = 7.6$, 2H, H-7), 1.76 (m, 4H, H-8/10), 1.47 (m, 2H, H-9) ppm; ^{13}C NMR (CDCl_3): $\delta = 161.9$ (C-2), 149.2 (C-6), 136.2 (C-4), 122.7 (C-3), 120.9 (C-5), 44.9 (C-11), 38.1 (C-7), 32.4 (C-10), 29.0 (C-8), 26.6 (C-9) ppm; MS (EI): m/z (%) = 182 (0.3), 148, 134, 120, 106, 93 (100), 78, 65, 51.

2-(6-Chlorohexyl)-pyridine (**3c**; $\text{C}_{11}\text{H}_{16}\text{ClN}$)

Reaction of 9.31 g (0.1 mol) **1** and 18.55 g (0.1 mol) 1-bromo-5-chloro-pentane affords 13.41 g (68 mmol, 68%) of **2c** (b.p.: 88°C at $1 \cdot 10^{-5}$ mbar).

^1H NMR (CDCl_3): $\delta = 8.47$ (ddd, $^3J = 4.9$, $^4J = 1.8$, $^5J = 1.0$, 1H, H-6), 7.52 (dt, $^3J = 7.6$, $^4J = 1.9$, 1H, H-4), 7.08 (d, $^3J = 7.7$, 1H, H-3), 7.03 (ddd, $^3J = 7.5$, $^4J = 4.9$, $^5J = 1.2$, 1H, H-5), 3.46 (t, $^3J = 6.7$, 2H, H-12), 2.74 (t, $^3J = 7.7$, 2H, H-7), 1.71 (m, 4H, H-8/11), 1.38 (m, 4H, H-9/10) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.1$ (C-2), 149.1 (C-6), 136.1 (C-4), 122.6 (C-3), 120.8 (C-5), 44.9 (C-12), 38.1 (C-7), 32.4 and 29.5 (C-8/11), 28.4 and 26.6 (C-9/10) ppm; MS (EI): m/z (%) = 196 (0.3), 162, 148, 134, 120, 106, 93 (100), 78, 65, 51.

2-(7-Chloroheptyl)-pyridine (**3d**; $\text{C}_{12}\text{H}_{18}\text{ClN}$)

Reaction of 9.31 g (0.1 mol) **1** and 19.95 g (0.1 mol) 1-bromo-6-chloro-hexane affords 16.97 g (80 mmol, 80%) **2d** (bp.: 82°C at $1 \cdot 10^{-5}$ mbar).

^1H NMR (CDCl_3): $\delta = 8.48$ (ddd, $^3J = 4.8$, $^4J = 1.8$, $^5J = 0.9$, 1H, H-6), 7.53 (dt, $^3J = 7.6$, $^4J = 1.9$, 1H, H-4), 7.09 (d, $^3J = 7.7$, 1H, H-3), 7.05 (ddd, $^3J = 7.5$, $^4J = 5.0$, $^5J = 1.2$, 1H, H-5), 3.47 (t, $^3J = 6.7$, 2H, H-13), 2.74 (t, $^3J = 7.7$, 2H, H-7), 1.71 (m, 4H, H-8/11), 1.38 (m, 6H, H-9/10/12) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.3$ (C-2), 149.2 (C-6), 136.1 (C-4), 122.6 (C-3), 120.8 (C-5), 45.0 (C-13), 38.3 (C-7), 32.5, 29.7 and 29.1 (C-8/11/12), 28.6 and 26.7 (C-9/10) ppm; MS (EI): m/z (%) = 210 (0.3), 176, 162, 148, 134, 120, 106, 93 (100), 78, 65, 51.

^a Lithiation may be also carried out with *n*-BuLi solution

1,2,3,4-Tetrahydroquinolizinium chloride (5a; C₉H₁₂ClN)

Compound **3a**, kept at 25°C for several hours, affords crystalline colourless **5a** in quantitative yield. **5a** is washed with hexane, dried under vacuum, and has to be stored in a dry atmosphere due to its hygroscopic character.

¹H NMR (CDCl₃): δ = 9.61 (dm, ³*J* = 6.3, 1H, H-6), 8.29 (dt, ³*J* = 7.8, ⁴*J* = 1.4, 1H, H-4), 7.89 (d, ³*J* = 7.7, 1H, H-3), 7.76 (t, ³*J* = 6.9, 1H, H-5), 4.91 (t, ³*J* = 5.9, 2H, H-7), 3.28 (t, ³*J* = 6.6, 2H, H-10), 2.07 (m, 2H, H-8), 1.97 (m, 2H, H-9) ppm; ¹³C NMR (CDCl₃): δ = 155.9 (C-2), 145.7 (C-6), 144.3 (C-4), 128.6 (C-3), 125.2 (C-5), 55.6 (C-7), 28.4 (C-10), 21.0 (C-8), 17.3 (C-10) ppm; MS (FAB): *m/z* (%) = 303 (27), 226 (37), 185 (25), 134 (100).

*7,8,9,10-Tetrahydro-6H-pyrido[1,2-*a*]azepinium chloride (5b; C₁₀H₁₄ClN)*

Compound **3b**, reacted at 130°C for 2 h, gives crystalline colourless **5b** in quantitative yield. **5b** is washed with hexane, dried under vacuum, and has to be stored in a dry atmosphere.

¹H NMR (CDCl₃): δ = 9.74 (dd, ³*J* = 6.1, ⁴*J* = 1.3, 1H, H-6), 8.32 (dt, ³*J* = 7.8, ⁴*J* = 1.5, 1H, H-4), 7.91 (dd, ³*J* = 8.0, ⁴*J* = 1.5, 1H, H-3), 7.75 (dd, ³*J* = 7.7, ⁴*J* = 6.5, ⁵*J* = 1.5, 1H, H-5), 5.06 (m, 2H, H-7), 3.30 (m, 2H, H-11), 1.74 (m, 6H, H-8/9/10) ppm; ¹³C NMR (CDCl₃): δ = 159.5 (C-2), 146.7 (C-6), 145.5 (C-4), 129.0 (C-3), 125.9 (C-5), 61.1 (C-7), 34.1 (C-11), 28.1, 26.8, 24.5 (C-8/9/10) ppm; MS (EI): *m/z* (%) = 331 (2), 294 (23), 184 (24), 148 (31), 147 (80), 146 (22), 132 (19), 120 (36), 118 (55), 106 (21), 93 (100), 78 (17); MS (FAB): *m/z* (%) = 331 (10), 295 (2), 148 (100), 132 (6), 118 (7), 106 (7).

*General procedure for the synthesis of ω -2-pyridyl-*n*-alkylphosphines*

To a vigorously stirred solution of (*i*-Pr)₂PH in THF (3 cm³ per mmol), one equivalent MeLi (1.6 *N* solution in diethyl ether) or *n*-BuLi (1.6 *N* solution in hexane) is added at -30°C. The mixture is allowed to warm up slowly to 25°C and is stirred for another 3 h. The light yellow phosphide solution is now transferred dropwise to a stirred solution of the 2-(ω -chloroalkyl)pyridine in THF (2 cm³ per mmol) at -50°C. The mixture is reacted for 12 h at 25°C. Volatile components are removed carefully at reduced pressure. The raw product is obtained from the residue by high vacuum condensation into a cold trap or by crystallization. Further purification is performed by vacuum distillation or recrystallization.

2-(4-Diisopropylphosphino-butyl)-pyridine (4a; C₁₅H₂₆NP)

Method 1: Analogous to the general procedure, 15.8 cm³ (25 mmol) MeLi, 2.99 g (25 mmol) (*i*-Pr)₂PH and 4.30 g (25 mmol) **3a** yield 3.69 g (15 mmol, 58%) **4a** after distillation (b.p.: 98°C at 4 · 10⁻⁶ mbar) as a light yellow liquid.

Method 2: A solution of 20 mmol **2** in 30 cm³ THF is prepared as described above. This solution is added dropwise to a solution of 3.89 g (20 mmol) Cl-(CH₂)₃-P(*i*-Pr)₂ in 30 cm³ THF at -60°C. After 90 min the reaction mixture is allowed to warm up to 25°C under stirring. The remaining red solution is refluxed for 4 h, hydrolyzed with 20 cm³ water, and extracted with diethyl ether. The organic phase is dried over Na₂SO₄ and filtered. The solvent is removed under vacuum, and the residue is condensed into a cold trap to yield 1.63 g (6.5 mmol, 32%) **4a**.

¹H NMR (CDCl₃): δ = 8.45 (ddd, ³*J* = 4.9, ⁴*J* = 1.8, ⁵*J* = 1.0, 1H, H-6), 7.51 (dt, ³*J* = 7.7, ⁴*J* = 1.9, 1H, H-4), 7.07 (dt, ³*J* = 7.8, ⁴*J* = 1.1, 1H, H-3), 7.01 (ddd, ³*J* = 7.5, ⁴*J* = 4.9, ⁵*J* = 1.2, 1H, H-5), 2.74 (t, ³*J* = 7.7, 2H, H-7), 1.77 (m, 2H, H-8), 1.63 (dsp, ³*J* = 7.1, ²*J*_{HP} = 2.8, 2H, H-12), 1.48 (m, 2H, H-9), 1.32 (m, 2H, H-10), 1.00 (dd, ³*J* = 7.2, ³*J*_{HP} = 13.8, 6H, H-13a), 0.97 (dd, ³*J* = 6.9, ³*J*_{HP} = 11.3, 6H, H-13b) ppm; ¹³C NMR (CDCl₃): δ = 162.1 (C-2), 149.1 (C-6), 136.1 (C-4), 122.5 (C-3), 120.7 (C-5), 38.0 (C-7), 31.6 (d, ¹*J*_{CPl} = 11.8, C-8), 27.9 (d, ¹*J*_{CPl} = 18.7, C-9), 23.1 (d,

$^1J_{\text{CPl}} = 12.2$, C-12), 21.4 (d, $^1J_{\text{CPl}} = 16.8$, C-10), 20.0 (d, $^2J_{\text{CPl}} = 15.6$, C-13a), 18.7 (d, $^2J_{\text{CPl}} = 9.2$, C-13b) ppm; ^{31}P NMR (CDCl_3): $\delta = 4.4$ ppm; MS (EI): m/z (%) = 251 (2), 236, 222, 208 (100), 166, 145, 132, 118, 106, 90, 76, 65, 51.

2-(5-Diisopropylphosphino-pentyl)-pyridine (4b; C₁₆H₂₈NP)

Analogous to the procedure described above, 21.9 cm³ (35 mmol) MeLi, 4.14 g (35 mmol) (*i*-Pr)₂PH, and 6.43 g (35 mmol) **3b** yield 7.76 g (29 mmol, 84%) **4b** after distillation (b.p.: 90°C at 4 · 10⁻⁶ mbar) as a colourless liquid.

^1H NMR (CDCl_3): $\delta = 8.50$ (ddd, $^3J = 4.8$, $^4J = 1.8$, $^5J = 1.0$, 1H, H-6), 7.55 (dt, $^3J = 7.7$, $^4J = 1.9$, 1H, H-4), 7.08 (m, 2H, H-3/5), 2.76 (t, $^3J = 7.8$, 2H, H-7), 1.71 (m, 2H, H-8), 1.67 (dsp, $^3J = 7.0$, $^2J_{\text{HP}} = 2.9$, 2H, H-13), 1.39–1.52 (m, 4H, H-9/10), 1.24–1.38 (m, 2H, H-11), 1.04 (dd, $^3J = 7.2$, $^3J_{\text{HP}} = 13.8$, 6H, H-14a), 1.02 (dd, $^3J = 7.0$, $^3J_{\text{HP}} = 11.1$, 6H, H-14b) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.2$ (C-2), 149.0 (C-6), 136.0 (C-4), 122.5 (C-3), 120.7 (C-5), 38.2 (C-7), 31.2 (d, $^3J_{\text{CPl}} = 11.8$, C-9), 29.5 (C-8), 27.9 (d, $^2J_{\text{CPl}} = 18.3$, C-10), 23.1 (d, $^1J_{\text{CPl}} = 12.2$, C-13), 21.4 (d, $^1J_{\text{CPl}} = 16.4$, C-11), 20.0 (d, $^2J_{\text{CPl}} = 15.3$, C-14a), 18.7 (d, $^2J_{\text{CPl}} = 9.2$, C-14b) ppm; ^{31}P NMR (CDCl_3): $\delta = 4.4$ ppm; MS (EI): m/z (%) = 265 (13), 250, 222, 180, 173 (100), 160, 148, 132, 118, 106, 90, 76, 65, 43.

2-(6-Diisopropylphosphino-hexyl)-pyridine (4c; C₁₇H₃₀NP)

21.9 cm³ (35 mmol) MeLi, 4.14 g (35 mmol) (*i*-Pr)₂PH, and 6.92 g (35 mmol) **3c** yield 8.75 g (31 mmol, 89%) **4c** after condensation at 4 · 10⁻⁶ mbar into a cold trap as a colourless liquid.

^1H NMR (CDCl_3): $\delta = 8.49$ (ddd, $^3J = 4.9$, $^4J = 1.8$, $^5J = 0.9$, 1H, H-6), 7.55 (dt, $^3J = 7.6$, $^4J = 1.9$, 1H, H-4), 7.10 (d, $^3J = 7.5$, 1H, H-3), 7.05 (ddd, $^3J = 7.4$, $^4J = 4.8$, $^5J = 1.2$, 1H, H-5), 2.76 (t, $^3J = 7.7$, 2H, H-7), 1.71 (m, 2H, H-8), 1.67 (dsp, $^3J = 7.1$, $^2J_{\text{HP}} = 2.8$, 2H, H-14), 1.20–1.50 (m, 8H, H-9/10/11/12), 1.04 (dd, $^3J = 7.2$, $^3J_{\text{HP}} = 13.9$, 6H, H-15a), 1.01 (dd, $^3J = 6.9$, $^3J_{\text{HP}} = 11.1$, 6H, H-15b) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.4$ (C-2), 149.2 (C-6), 136.1 (C-4), 122.6 (C-3), 120.8 (C-5), 38.4 (C-7), 31.4 (d, $^3J_{\text{CPl}} = 11.4$, C-10), 29.8 and 29.1 (C-8/9), 28.1 (d, $^2J_{\text{CPl}} = 18.3$, C-11), 23.2 (d, $^1J_{\text{CPl}} = 12.2$, C-14), 21.6 (d, $^1J_{\text{CPl}} = 16.4$, C-12), 20.1 (d, $^2J_{\text{CPl}} = 15.6$, C-15a), 18.8 (d, $^2J_{\text{CPl}} = 9.5$, C-15b) ppm; ^{31}P NMR (CDCl_3): $\delta = 4.5$ ppm; MS (EI): m/z (%) = 279 (22), 264, 236, 194, 187 (100), 173, 162, 145, 132, 118, 106, 93, 90, 76, 65, 43.

2-(7-Diisopropylphosphino-heptyl)-pyridine (4d; C₁₈H₃₂NP)

21.9 cm³ (35 mmol) MeLi, 4.14 g (35 mmol) (*i*-Pr)₂PH, and 7.41 g (35 mmol) **3d** yield 6.93 g (24 mmol, 67%) **4d** after distillation (b.p.: 124°C at 2 · 10⁻⁴ mbar) as a colourless liquid.

^1H NMR (CDCl_3): $\delta = 8.48$ (ddd, $^3J = 4.9$, $^4J = 1.8$, $^5J = 1.0$, 1H, H-6), 7.53 (dt, $^3J = 7.7$, $^4J = 1.9$, 1H, H-4), 7.09 (d, $^3J = 7.7$, 1H, H-3), 7.04 (ddd, $^3J = 7.5$, $^4J = 5.0$, $^5J = 1.2$, 1H, H-5), 2.74 (t, $^3J = 7.8$, 2H, H-7), 1.69 (m, 2H, H-8), 1.66 (dsp, $^3J = 7.1$, $^2J_{\text{HP}} = 2.8$, 2H, H-15), 1.24–1.45 (m, 10H, H-9/10/11/12/13), 1.03 (dd, $^3J = 7.2$, $^3J_{\text{HP}} = 13.8$, 6H, H-16a), 1.00 (dd, $^3J = 7.0$, $^3J_{\text{HP}} = 11.6$, 6H, H-16b) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.4$ (C-2), 149.1 (C-6), 136.1 (C-4), 122.6 (C-3), 120.8 (C-5), 38.4 (C-7), 31.4 (d, $^3J_{\text{CPl}} = 11.4$, C-11), 29.8 (C-8), 29.24 and 29.15 (C-9/10), 28.1 (d, $^2J_{\text{CPl}} = 17.9$, C-12), 23.2 (d, $^1J_{\text{CPl}} = 11.8$, C-15), 21.5 (d, $^1J_{\text{CPl}} = 16.8$, C-13), 20.1 (d, $^2J_{\text{CPl}} = 15.6$, C-16a), 18.8 (d, $^2J_{\text{CPl}} = 9.1$, C-16b) ppm; ^{31}P NMR (CDCl_3): $\delta = 4.4$ ppm; MS (EI): m/z (%) = 293 (14), 278, 250, 201, 187, 176, 162, 145, 132, 118, 106, 93, 90 (100), 76, 65, 61, 43.

2-(5-Diphenylphosphino-pentyl)-pyridine (4e; C₂₂H₂₄NP)

12.8 cm³ (20 mmol) *n*-BuLi, 3.80 g (20 mmol) Ph₂PH, and 3.75 g (20 mmol) **3b** yield 4.92 g (15 mmol, 72%) **4e** after crystallization from hexane at –35°C as colourless crystals (m.p.: 44°C).

^1H NMR (CDCl_3): $\delta = 8.50$ (ddd, $^3J = 4.6$, $^4J = 1.9$, $^5J = 1.1$, 1H, H-6), 7.54 (dt, $^3J = 7.6$, $^4J = 1.9$, 1H, H-4), 7.40 (m, 4H, H-14), 7.31 (m, 6H, H-15/16), 7.08 (d, $^3J = 7.7$, 1H, H-3), 7.05 (dd, $^3J = 7.5$, $^5J = 1.3$, 1H, H-5), 2.74 (t, $^3J = 7.6$, 2H, H-7), 2.04 (m, 2H, H-11), 1.73 (m, 2H, H-8), 1.49 (m, 4H, H-9/10) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.2$ (C-2), 149.2 (C-6), 138.9 (d, $^1J_{\text{CPl}} = 13.0$, C-13), 136.1 (C-4), 132.6 (d, $^2J_{\text{CPl}} = 18.3$, C-14), 128.4 (C-16), 128.3 (d, $^3J_{\text{CPl}} = 6.9$, C-15), 122.6 (C-3), 120.8 (C-5), 38.2 (C-7), 30.9 (d, $^3J_{\text{CPl}} = 12.6$, C-9), 29.4 (C-8), 27.9 (d, $^1J_{\text{CPl}} = 11.5$, C-11), 25.8 (d, $^2J_{\text{CPl}} = 16.0$, C-10) ppm; ^{31}P NMR (CDCl_3): $\delta = -15.6$ ppm; MS (CI): m/z (%) = 334 (100), 255, 241, 199, 183, 148, 134, 108, 93.

2-(6-Diphenylphosphino-hexyl)-pyridine (**4f**; $\text{C}_{23}\text{H}_{26}\text{NP}$)

Analogous to the synthesis of **4c**, 18.4 cm^3 (29 mmol) *n*-BuLi, 5.47 g (29 mmol) Ph_2PH , and 5.81 g (29 mmol) **3c** yield 7.92 g (23 mmol, 78%) **4f** after crystallization from hexane at -35°C as colourless crystalline needles (m.p.: 48°C).

^1H NMR (CDCl_3): $\delta = 8.51$ (ddd, $^3J = 4.9$, $^4J = 1.8$, $^5J = 0.9$, 1H, H-6), 7.55 (dt, $^3J = 7.6$, $^4J = 1.8$, 1H, H-4), 7.28–7.44 (m, 10H, H-15/16/17), 7.07 (m, 2H, H-3/5), 2.75 (t, $^3J = 7.7$, 2H, H-7), 2.03 (m, 2H, H-12), 1.70 (m, 2H, H-8), 1.27–1.54 (m, 6H, H-9/10/11) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.3$ (C-2), 149.2 (C-6), 139.0 (d, $^1J_{\text{CPl}} = 13.4$, C-14), 136.1 (C-4), 132.6 (d, $^2J_{\text{CPl}} = 18.3$, C-15), 128.4 (C-17), 128.3 (d, $^3J_{\text{CPl}} = 6.5$, C-16), 122.6 (C-3), 120.8 (C-5), 38.3 (C-7), 31.0 (d, $^3J_{\text{CPl}} = 12.6$, C-10), 29.7 (C-8), 28.9 (C-9), 28.0 (d, $^1J_{\text{CPl}} = 11.4$, C-12), 25.8 (d, $^2J_{\text{CPl}} = 16.0$, C-11) ppm. ^{31}P NMR (CDCl_3): $\delta = -15.5$ ppm; MS (CI): m/z (%) = 348 (100), 255, 241, 199, 187, 162, 148, 134, 109, 93.

2-(7-Diphenylphosphino-heptyl)-pyridine (**4g**; $\text{C}_{24}\text{H}_{28}\text{NP}$)

Analogous to the synthesis of **4e**, 18.8 cm^3 (30 mmol) *n*-BuLi, 5.59 g (30 mmol) Ph_2PH , and 6.35 g (30 mmol) **3d** yield 8.60 g (24 mmol, 79%) **4g** after crystallization from hexane at -35°C as colourless crystalline needles (m.p.: 30°C).

^1H NMR (CDCl_3): $\delta = 8.51$ (ddd, $^3J = 4.9$, $^4J = 1.5$, $^5J = 0.9$, 1H, H-6), 7.54 (dt, $^3J = 7.6$, $^4J = 1.9$, 1H, H-4), 7.28–7.46 (m, 10H, H-16/17/18), 7.07 (m, 2H, H-3/5), 2.76 (t, $^3J = 7.8$, 2H, H-7), 2.03 (m, 2H, H-13), 1.71 (m, 2H, H-8), 1.38 (m, 8H, H-9/10/11/12) ppm; ^{13}C NMR (CDCl_3): $\delta = 162.4$ (C-2), 149.1 (C-6), 139.0 (d, $^1J_{\text{CPl}} = 13.0$, C-15), 136.1 (C-4), 132.6 (d, $^2J_{\text{CPl}} = 18.3$, C-16), 128.33 (C-18), 128.27 (d, $^3J_{\text{CPl}} = 6.9$, C-17), 122.5 (C-3), 120.7 (C-5), 38.3 (C-7), 31.0 (d, $^3J_{\text{CPl}} = 13.0$, C-11), 29.7 (C-8), 29.1 and 29.0 (C-9/10), 27.9 (d, $^1J_{\text{CPl}} = 11.1$, C-13), 25.8 (d, $^2J_{\text{CPl}} = 16.0$, C-12) ppm; ^{31}P NMR (CDCl_3): $\delta = -15.5$ ppm; MS (CI): m/z (%) = 362 (100), 284, 269, 255, 176, 109, 93.

2-(Diisopropylphosphino-methyl)-pyridine (**6a**; $\text{C}_{12}\text{H}_{20}\text{NP}$)

A solution of 2.33 g (25 mmol) **1** in 50 cm^3 *THF* is treated with one equivalent *n*-BuLi at -50°C . The mixture is stirred for one hour at 25°C to give a clear red solution of **2** which is slowly transferred to a well stirred solution of 3.82 g (25 mmol) (*i*-Pr) $_2\text{PCl}$ in 50 cm^3 *THF* at -50°C . After the reaction mixture has been stirred for 12 h, the volatile components are removed carefully at reduced pressure. 4.05 g (19 mmol, 77%) **6a** are obtained as a yellow liquid from the residue by distillation (b.p.: 68°C at $4 \cdot 10^{-6}$ mbar).

^1H NMR (CDCl_3): $\delta = 8.41$ (ddd, $^3J = 4.9$, $^4J = 1.8$, $^5J = 0.9$, 1H, H-6), 7.49 (dt, $^3J = 7.6$, $^4J = 1.9$, 1H, H-4), 7.24 (ddt, $^3J = 7.9$, $^5J = 0.9$, $^4J_{\text{HP}} = 0.8$, 1H, H-3), 6.99 (ddd, $^3J = 7.4$, $^4J = 5.0$, $^5J = 1.2$, 1H, H-5), 2.94 (d, $^2J_{\text{HP}} = 2.2$, 2H, H-7), 1.75 (dsp, $^3J = 7.1$, $^2J_{\text{HP}} = 1.9$, 2H, H-8), 1.00 (dd, $^3J = 7.0$, $^3J_{\text{HP}} = 11.5$, 6H, H-9a), 0.99 (dd, $^3J = 7.2$, $^3J_{\text{HP}} = 13.6$, 6H, H-9b) ppm; ^{13}C NMR (CDCl_3): $\delta = 160.6$ (d, $^4J_{\text{CPl}} = 8.4$, C-2), 149.0 (C-6), 135.9 (C-4), 123.5 (d, $^3J_{\text{CPl}} = 6.9$, C-3), 120.5

(d, $^1J_{\text{CPl}} = 1.5$, C-5), 32.3 (d, $^1J_{\text{CPl}} = 22.1$, C-7), 23.4 (d, $^1J_{\text{CPl}} = 13.7$, C-8), 19.6 (d, $^2J_{\text{CPl}} = 14.5$, C-9a), 18.8 (d, $^2J_{\text{CPl}} = 10.7$, C-9b), MS (EI): m/z (%) = 209 (2.4), 194, 166, 150, 135, 124 (100), 93, 78, 65.

2-(bis-Diisopropylphosphino-methyl)-pyridine (**7a**; C₁₈H₃₃NP₂)

Analogous to the synthesis of **6a**, 6.2 cm³ (10 mmol) *n*-BuLi, 2.09 g (10 mmol) **6a** and 1.53 g (10 mmol) (*i*-Pr)₂PCL yield 1.68 g (5 mmol, 52%) **7a** as a light brown viscous liquid (b.p.: 108°C at 3 · 10⁻⁶ mbar).

¹H NMR (CDCl₃): $\delta = 8.42$ (ddd, $^3J = 4.8$, $^4J = 1.9$, $^5J = 0.9$, 1H, H-6), 7.47 (dt, $^3J = 7.7$, $^4J = 1.9$, 1H, H-4), 7.13 (ddt, $^3J = 7.9$, $^5J = 1.0$, $^4J_{\text{HP}} = 0.3$, 1H, H-3), 6.97 (ddd, $^3J = 7.4$, $^4J = 4.8$, $^5J = 1.2$, 1H, H-5), 3.51 (s, 1H, H-7), 2.00 (tsp, $^3J = 7.1$, $^2J_{\text{HP}} = 1.8$, 2H, H-9a), 1.87 (tsp, $^3J = 7.2$, $^2J_{\text{HP}} = 1.5$, 2H, H-9b), 1.17 (dt, $^3J = 7.2$, $^3J_{\text{HP}} = 13.2$, 6H, H-10a), 1.08 (dt, $^3J = 7.0$, $^3J_{\text{HP}} = 12.4$, 6H, H-10a'), 0.97 (dt, $^3J = 7.4$, $^3J_{\text{HP}} = 15.1$, 6H, H-10b), 0.63 (dt, $^3J = 7.2$, $^3J_{\text{HP}} = 10.3$, 6H, H-10b') ppm; ¹³C NMR (CDCl₃): 160.2 (t, $^2J_{\text{CPl}} = 2.7$, C-2), 148.9 (C-6), 135.3 (C-4), 123.6 (t, $^3J_{\text{CPl}} = 3.8$, C-3), 120.3 (C-5), 38.4 (t, $^1J_{\text{CPl}} = 33.9$, C-7), 22.2 (t, $^2J_{\text{CPl}} = 10.7$, C-10b), 22.0 (t, $^1J_{\text{CPl}} = 5.0$, C-9a), 21.8 (t, $^1J_{\text{CPl}} = 6.9$, C-9b), 20.5 (t, $^2J_{\text{CPl}} = 8.4$, C-10a), 20.0 (t, $^2J_{\text{CPl}} = 8.0$, C-10a'), 19.3 (t, $^2J_{\text{CPl}} = 3.8$, C-10b') ppm; ³¹P NMR (CDCl₃): $\delta = 12.6$ ppm; MS (CI): m/z (%) = 326 (100), 282, 251, 226, 210, 196, 166, 135, 124, 93.

2,6-bis-(Diisopropylphosphino-methyl)-pyridine (**9**; C₁₉H₃₅NP)

A solution of 2.62 g (22 mmol) (*i*-Pr)₂PH in 20 cm³ THF is treated with one equivalent *n*-BuLi at -50°C. The mixture is stirred for 3 h without further cooling to yield a yellow phosphide solution. This solution is slowly transferred to a stirred solution of 1.96 g (11 mmol) 2,6-bis(chloromethyl)-pyridine (**8**) in 30 ml THF at -50°C. After the reaction mixture has been stirred for 12 h, the volatile components are removed carefully at reduced pressure. 2.29 g (6.5 mmol, 59%) **6a** are obtained as a light yellow liquid from the residue by condensation into a cold trap at 4 · 10⁻⁶ mbar.

¹H NMR (CDCl₃): $\delta = 7.40$ (dd, $^3J = 7.6$, 1H, H-4), 7.06 (d, $^3J = 7.5$, 2H, H-3), 2.91 (d, $^2J_{\text{HP}} = 2.2$, 2H, H-5), 1.76 (dsp, $^3J = 7.1$, $^2J_{\text{HP}} = 2.1$, 4H, H-7), 1.02 (dd, $^3J = 7.2$, $^3J_{\text{HP}} = 11.5$, 12H, H-8a), 1.01 (dd, $^3J = 7.2$, $^3J_{\text{HP}} = 13.5$, 12H, H-8b) ppm; ¹³C NMR (CDCl₃): $\delta = 159.7$ (d, $^2J_{\text{CPl}} = 8.4$, C-2), 136.0 (C-4), 120.3 (dd, $^3J_{\text{CPl}} = 8.0$, $^5J_{\text{CPl}} = 1.9$, C-3), 32.4 (d, $^1J_{\text{CPl}} = 21.4$, C-5), 23.4 (d, $^1J_{\text{CPl}} = 13.7$, C-7), 19.6 (d, $^2J_{\text{CPl}} = 14.5$, C-8b), 19.0 (d, $^2J_{\text{CPl}} = 10.7$, C-8a) ppm; ³¹P NMR (CDCl₃): $\delta = 12.7$ ppm; MS (CI): m/z (%) = 340 (100), 296, 254, 240, 223, 135, 119.

Acknowledgements

We are grateful to the Institute of Organic Chemistry, Jena, and to the Microanalytical Laboratory Kolbe, Mülheim a. d. Ruhr, for performing the elemental analyses. We also thank Dr. M. Poppitz for mass spectrometric analyses and Dr. H. Schreer for molecular mass determinations. This work was financially supported by the Max-Planck-Gesellschaft.

References

- [1] Jeffrey JC, Rauchfuss TB (1979) Inorg Chem **18**: 2658
- [2] Pitter S, Dinjus E, Jung B, Görls H (1996) Z Naturforsch B **51b**: 934
- [3] Pitter S, Dinjus E (1997) J Mol Cat A **125**: 39
- [4] Newkome R (1993) Chem Rev **93**: 2067
- [5] Drent E, Arnoldy P, Budzelaar PHM (1993) J Organomet Chem **455**: 247
- [6] Chan WH, Zhang ZZ, Mak TCW, Che CM (1998) J Chem Soc Dalton Trans 797

- [7] Budzelaar PHM (1998) *J Org Chem* **63**: 1131
- [8] Chelucci G, Cabras MA, Botteghi C, Marchetti M (1994) *Tetrahedron: Asymmetry* **5**: 299
- [9] Takashi H, Yoshio U, Hirofumi Y (1984) *J Phys Chem* **88**: 5150
- [10] Moyhenan TM, Schofield K, Jones RAY, Katritzky AR (1962) *J Chem Soc* 2637
- [11] Miyadera T, Kishada Y (1969) *Tetrahedron* **25**: 209
- [12] Murphy JA, Sherburn MS (1991) *Tetrahedron* **47**: 4077
- [13] Murphy JA, Dickinson JM (1990) *J Chem Soc Chem Commun* 439
- [14] Alvarez M, Lugan N, Mathieu R (1994) *J Chem Soc Dalton Trans* 2755
- [15] Anderson MP, Mattson BM, Pignolet LH (1983) *Inorg Chem* **22**: 2644
- [16] Cristau H-J, Chene A, Christol H (1980) *Synthesis* **7**: 551
- [17] Ziessel R (1989) *Tetrahedron Lett* **30**: 463
- [18] Jiang Q, van Plew D, Murtuza S, Zhang X (1996) *Tetrahedron Lett* **6**: 797

Received November 9, 1998. Accepted (revised) January 19, 1999